Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 3Terminated 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 3pembrolizumab 2Etoposide 2Docetaxel 2Carboplatin 2durvalumab 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Radionuclide Imaging 1Radiation 1Prednisone 1Positron-Emission Tomography 1Platinum 1Paclitaxel 1Nivolumab 1Methods 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Injections 1Exercise Therapy 1Erlotinib Hydrochloride 1Eflornithine 1Clinical Protocols 1CTLA-4 Antigen 1Blood Specimen Collection 1Biopsy 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Lung Neoplasms × CTLA-4 Antigen × Clear all
NCT04929041 2026-05-13

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

National Cancer Institute (NCI)

Phase 2/3 Suspended
427 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡